IP Library Patent Application 14564507
Patent Application
App. No. 14/564,507

PHENOXYMETHYL HETEROCYCLIC COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/564,507
Abstract

Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.

Claims (31)

1 . A compound of Formula (I) and pharmaceutically acceptable salts thereof,

wherein:

HET is selected from A29 and A31

wherein the left most radical is connected to the X group in Formula (I);

X is selected from optionally substituted aryl and optionally substituted heteroaryl, wherein the substituents are selected from C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyloxy, C 1 -C 4 alkoxy, CF 3 , carboxy, alkoxyalkyl, C 1 -C 4 cycloalkylalkoxy, amino, alkylamino, dialkylamino, amido, alkylamido, dialkylamido, thioalkyl, halogen, cyano, alkylsulfonyl and nitro; and

Z is selected from pyridin-2-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-b]pyridazin-2-yl, and imidazo[1,2-b]pyridazin-6-yl, each of which can be optionally substituted, wherein the substituents are selected from C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyloxy, C 1 -C 4 alkoxy, CF 3 , carboxy, alkoxyalkyl, C 1 -C 4 cycloalkylalkoxy, amino, alkylamino, dialkylamino, amido, alkylamido, dialkylamido, thioalkyl, halogen, cyano, alkylsulfonyl and nitro; and

each R 2 is independently selected from optionally fluoro substituted C 1 -C 4 alkyl or two R 2 groups taken together with the carbon to which they are attached form a 3 membered cycloalkyl ring.

2 - 35 . (canceled)

36 . A method for making 4-(4-hydroxyphenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof, the method comprising using Suzuki coupling to obtain 4-(4-hydroxyphenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof from 4-bromo-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one.

37 . The method of claim 36 , conducted in a polar solvent mixture.

38 . The method of claim 37 , wherein the polar solvent mixture comprises water.

39 . The method of claim 36 , conducted in the presence of a catalyst.

40 . The method of claim 39 , wherein the catalyst is a palladium(0) or palladium(II) catalyst.

41 . The method of claim 36 conducted in the presence of a base.

42 . The method of claim 41 , wherein the base is selected from the group consisting of potassium carbonate, sodium carbonate and cesium carbonate.

43 . The method of claim 36 , further comprising isolating 4-(4-hydroxyphenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof.

44 . A method for making 4-(4-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof,

the method comprising contacting 4-(4-hydroxyphenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one

with a compound of formula

to provide 4-(4-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof.

45 . The method of claim 44 , conducted in a polar solvent.

46 . The method of claim 45 , wherein the polar solvent is CH 3 CN or DMF.

47 . The method of claim 44 conducted in the presence of a base.

48 . The method of claim 47 , wherein the base is selected from the group consisting of potassium carbonate, sodium carbonate and cesium carbonate.

49 . The method of claim 44 , further comprising isolating 4-(4-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof.

50 . A method for making 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof,

the method comprising reducing 4-(4-((6-chloroimidazo[1,2-b]pyridazin-2-yl)methoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one to provide 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof.

51 . The method of claim 50 , conducted in the presence of a catalyst.

52 . The method of claim 51 , wherein the catalyst is a palladium(0) or palladium(II) catalyst.

53 . The method of claim 50 , conducted in the presence of hydrogen.

54 . The method of claim 50 , further comprising isolating 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a salt thereof.

Assignments (3)
SECURITY INTEREST Recorded Jul 5, 2016
From: FORUM PHARMACEUTICALS INC.
To: FMR LLC
Reel/Frame 039254/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2015
From: RIPKA, AMY; SHAPIRO, GIDEON; CHESWORTH, RICHARD
To: ENVIVO PHARMACEUTICALS, INC.
Reel/Frame 036152/0490 →
CHANGE OF NAME Recorded Jul 22, 2015
From: ENVIVO PHARMACEUTICALS, INC.
To: FORUM PHARMACEUTICALS INC.
Reel/Frame 036158/0876 →